Clinicians first saw medetomidine in Philadelphia’s drug supply in spring 2024, when overdoses left patients unusually sedated with low heart rates after naloxone. By autumn, severe withdrawal symptoms showed the risk had grown. The American Society of Addiction Medicine released the first U.S. guid